Diseases Invented by Drug Companies: 5 Shocking Cases You Need to Know

You take a pill every morning, but have you ever wondered who decided you were sick in the first place?

What if the “disease” you’ve been treating for years was engineered not in a lab, but in a boardroom?

That might sound like the opening line of a conspiracy thriller. But the practice of pharmaceutical companies influencing, expanding, or outright creating disease categories to sell medications is so well-documented that the medical community has a formal term for it: disease mongering. It was coined by health journalist Lynn Payer back in 1992 and has since been explored in peer-reviewed journals, investigative documentaries, and books by physicians themselves.

Let’s be clear about something right up front. This article is not anti-medicine. It is not anti-science. Pharmaceutical companies have produced life-saving drugs that have extended and improved millions of lives. Vaccines, antibiotics, cancer therapies, insulin. The list of genuine medical triumphs is long and worth celebrating.

But the pharmaceutical industry is also, at its core, an industry. It answers to shareholders. It operates under profit incentives. And when a company spends more on marketing than on research and development (which many do), the line between genuine medical need and manufactured demand can become uncomfortably blurry.

The concept of diseases invented by drug companies is not about dismissing real suffering. People who are diagnosed with the conditions we’ll discuss in this article often experience genuine distress, real symptoms, and legitimate struggles. The question is not whether the suffering is real. It’s whether the framing of that suffering as a specific “disease” requiring a specific pharmaceutical product was driven by science or by sales strategy.

In this deep dive, we’re going to examine five conditions where the evidence strongly suggests that drug companies played a central, and sometimes troubling, role in defining, popularizing, or dramatically expanding a diagnosis to create a market for their products. We’ll look at the marketing campaigns, the clinical trial strategies, the physician influence tactics, and the money trails. And we’ll hear from the researchers, doctors, and journalists who blew the whistle.

By the end, you’ll have a much sharper lens for evaluating the next time someone tells you there’s a pill for what ails you.

Disclaimer

This article is for educational and informational purposes only. It is not medical advice. Nothing in this post should be interpreted as a recommendation to start, stop, or change any medication or treatment plan.

If you are currently taking prescribed medication for any condition discussed here, do not stop or alter your treatment without consulting your doctor. Many of the conditions discussed involve real symptoms that genuinely benefit from medical intervention in certain patients. The critique here is directed at industry marketing practices, diagnostic boundary expansion, and the medicalization of normal human experience, not at individuals who are seeking help.

Always consult a qualified healthcare professional before making decisions about your health.

What Does “Diseases Invented by Drug Companies” Actually Mean?

Before we get into the specific cases, it’s important to understand what we’re actually talking about when we say diseases invented by drug companies. This phrase doesn’t necessarily mean a pharmaceutical corporation sat down and fabricated a condition from thin air (though, as you’ll see, some cases come remarkably close).

More often, disease mongering operates through subtler mechanisms.

The Spectrum of Disease Invention

The strategies tend to fall along a spectrum:

• Rebranding normal life as a medical condition. Shyness becomes “Social Anxiety Disorder.” Aging bones become “osteopenia.” A child’s restlessness becomes a psychiatric diagnosis. Ordinary human experiences are reframed as pathologies requiring pharmaceutical intervention.

• Expanding diagnostic boundaries. A condition that legitimately affects a small number of people is redefined so broadly that millions of previously healthy individuals suddenly qualify for treatment. Thresholds for cholesterol, blood pressure, blood sugar, and bone density have all been lowered over the decades, often by expert panels with undisclosed financial ties to drug makers.

• Raising awareness of obscure conditions. A little-known or rarely diagnosed condition is suddenly the subject of a massive “awareness campaign” funded by the company that just happens to make the treatment. The campaign always arrives suspiciously close to a drug’s FDA approval date.

• Turning risk factors into diseases. Having a slightly elevated number on a lab test is treated as a disease in itself, rather than one factor among many in a complex health picture. You’re not “at slightly higher statistical risk.” You’re “sick” and need medication.

• Creating a condition to match a molecule. Sometimes a drug is developed, a use is found, and then the condition it treats is popularized. The drug comes first, the disease second.

The Academic Foundation

This isn’t fringe thinking. In 2006, the peer-reviewed journal PLOS Medicine published an entire special issue on disease mongering, featuring contributions from researchers, physicians, and ethicists around the world. The editors wrote that disease mongering “is now part of the global health debate” and called it “a threat to public health.”

Dr. Ray Moynihan, an Australian health researcher and one of the world’s leading authorities on the topic, has described the process bluntly: “A lot of money can be made from healthy people who believe they are sick.”

The evidence is not lacking. What’s often lacking is public awareness. So let’s change that.

The Playbook: How Drug Companies Sell Medications by Selling Diseases First

Understanding the five specific cases requires understanding the playbook. Because while the details differ, the strategy that drug companies use to sell medications through disease creation follows a remarkably consistent pattern.

Step 1: Fund the Science (and the Scientists)

Pharmaceutical companies fund a staggering proportion of clinical research. They design the trials, analyze the data, and ghostwrite the papers. They also cultivate relationships with “Key Opinion Leaders” (KOLs), the prominent physicians and academics who serve on guideline committees and speak at medical conferences.

These KOLs receive consulting fees, speaking fees, research grants, and sometimes equity stakes. A 2017 study published in the British Medical Journal found that the majority of physicians on panels that create clinical practice guidelines have financial ties to the industry.

This doesn’t mean every funded researcher is corrupt. But it creates an environment where diagnostic boundaries tend to expand in one direction: toward more people qualifying for medication.

Step 2: Define the Disease Broadly

Once you have sympathetic researchers and a body of industry-funded literature, the next step is to push for the broadest possible definition of the condition. The broader the definition, the larger the patient population, and the larger the market.

• Lower the cholesterol threshold, and 36 million more Americans suddenly need statins.
• Redefine “prediabetes,” and half the adults in China qualify.
• Expand the criteria for ADHD, and diagnosis rates triple in a decade.

Step 3: Launch an “Awareness” Campaign

This is where the marketing machine kicks in. Drug companies cannot legally advertise a drug for an unapproved use, but they can fund “disease awareness” campaigns that encourage people to “talk to your doctor” about a set of symptoms.

These campaigns use websites, celebrity spokespeople, social media influencers, patient advocacy groups (often industry-funded), and direct-to-consumer advertising (legal only in the United States and New Zealand). The message is always the same: you might have this condition and not know it. There’s help available. Ask your doctor.

Step 4: Arm the Sales Reps

Pharmaceutical sales representatives visit doctors’ offices with samples, studies, and scripted talking points. They bring lunch. They bring gifts. They bring data (carefully selected) showing the drug’s benefits. They minimize the side effects. They create a sense of urgency.

According to data compiled by the World Health Organization, the global pharmaceutical industry employs roughly one sales representative for every five practicing physicians.

Step 5: Profit

Once the disease is widely recognized, the diagnostic criteria are broad, physicians are educated (or influenced), and patients are primed to ask for treatment, prescriptions flow. Revenue follows. And the cycle reinforces itself.

Now, with that playbook in mind, let’s look at five cases where this machinery was deployed with remarkable effectiveness.

Case #1: Social Anxiety Disorder and the Diseases Invented by Drug Companies to Sell Paxil

If there is a single case study that best illustrates how diseases are invented by drug companies to sell medications, it is the story of Social Anxiety Disorder (SAD) and GlaxoSmithKline’s antidepressant Paxil (paroxetine).

From Shyness to Disorder

Shyness has been part of the human experience since humans have existed. Some people are gregarious. Others are reserved. Some find social situations energizing. Others find them draining. For most of human history, this was understood as temperamental variation, not pathology.

“Social phobia” appeared in the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980, defined narrowly as a severe, debilitating fear of specific social situations. It was considered rare, estimated to affect about 2% of the population, and was largely unknown outside psychiatric circles.

Then GlaxoSmithKline needed a new market for Paxil.

The Marketing Machine

In the late 1990s, Paxil was facing stiff competition in the antidepressant market from Prozac and Zoloft. GSK needed a new indication. In 1999, the FDA approved Paxil for the treatment of “Social Anxiety Disorder,” a rebranded and broadened version of social phobia.

What followed was one of the most aggressive disease-awareness campaigns in pharmaceutical history. GSK hired the public relations firm Cohn & Wolfe, which developed the tagline: “Imagine Being Allergic to People.”

The campaign included:

• Television commercials showing ordinary people struggling with everyday social situations (ordering coffee, meeting coworkers, attending parties)
• Print ads in major magazines and newspapers
• A dedicated website encouraging visitors to take a self-assessment quiz
• Funding for patient advocacy groups and “awareness” events
• A media blitz with press releases claiming that Social Anxiety Disorder affected “over 10 million Americans” and was “the third most common psychiatric disorder in the United States”

That last claim is worth pausing on. How did a condition considered rare just a decade earlier suddenly become the third most common psychiatric disorder? The answer lies in the diagnostic criteria.

Expanding the Boundaries

The definition of SAD was broadened to include not just severe, debilitating social phobia but a wide range of common social discomforts: fear of public speaking, anxiety about eating in front of others, discomfort at parties, nervousness during job interviews.

By these criteria, a significant portion of the population qualified. And because the “awareness” campaign was so effective, millions of people who had previously thought of themselves as shy, introverted, or simply reserved began to wonder if they had a medical condition.

The Numbers Tell the Story

Paxil’s sales for Social Anxiety Disorder exploded. By 2001, Paxil was generating over $3 billion in annual revenue, making it one of the best-selling drugs in the world. Prescriptions for social anxiety specifically contributed a massive share of that growth.

The Criticism

Investigative journalist Brendan Koerner wrote in Mother Jones that GSK’s campaign “didn’t just sell a drug. It sold an illness.” Dr. Christopher Lane, author of Shyness: How Normal Behavior Became a Sickness, documented in meticulous detail how the DSM committees that expanded the diagnostic criteria for social anxiety included members with financial ties to pharmaceutical companies.

The broader concern, raised by numerous psychiatrists and psychologists, is not that severe social anxiety doesn’t exist. It does. And for those individuals, medication can be genuinely life-changing. The concern is that the pharmaceutical marketing machine took a narrow, severe condition, expanded its boundaries to encompass a huge portion of the normally shy population, and sold them a drug with significant side effects (including sexual dysfunction, weight gain, and a notoriously difficult withdrawal syndrome) for a “disease” they didn’t have.

Case #2: Female Sexual Dysfunction, the Disease Drug Companies Created to Sell a Pink Pill

The story of Female Sexual Dysfunction (FSD) is perhaps the most nakedly transparent example of diseases invented by drug companies to sell medications. It involves a pharmaceutical industry that looked at the billion-dollar success of Viagra and asked a very simple question: can we do the same thing for women?

The Viagra Gold Rush

When Pfizer’s Viagra launched in 1998 to treat erectile dysfunction in men, it became the fastest-selling drug in history at that time. It generated $1 billion in revenue in its first year alone. The pharmaceutical industry immediately recognized the potential of a female equivalent.

But there was a problem. Female sexuality is complex, and low sexual desire in women can be influenced by relationship dynamics, stress, hormonal changes, body image, past trauma, and dozens of other factors. There was no clear-cut physiological mechanism analogous to male erectile dysfunction.

So the industry needed a disease first, and a drug second.

Building the Disease

In 1999, an article appeared in the Journal of the American Medical Association (JAMA) claiming that 43% of American women suffered from “Female Sexual Dysfunction.” The figure made international headlines. Nearly half of all women were sexually dysfunctional? It was a staggering claim.

But the study’s methodology was deeply flawed. It was based on a survey that asked women if they had experienced any of seven common sexual concerns (such as lack of desire, difficulty with arousal, or pain during intercourse) for at least two months in the past year. If a woman checked even one box, she was classified as having FSD.

Critically, the survey did not ask whether the women were bothered by the issue. A woman who experienced reduced desire during a period of intense work stress but wasn’t particularly distressed by it was classified identically to a woman with a severe, chronic condition.

Two of the study’s three authors had financial ties to Pfizer.

The “Even the Score” Campaign

Fast forward to the 2010s. Sprout Pharmaceuticals was seeking FDA approval for flibanserin, a drug originally developed as an antidepressant that had failed to outperform placebo for depression. But it showed a very modest effect on sexual desire in premenopausal women.

The FDA rejected flibanserin twice, in 2010 and 2013, citing minimal efficacy and significant side effects (including dizziness, nausea, fatigue, and dangerous interactions with alcohol).

Sprout responded with a campaign called “Even the Score,” framed as a feminist issue. The argument: the FDA had approved 26 drugs for male sexual dysfunction but zero for women. (The “26 drugs” claim was misleading, as most were variations of the same few molecules.) The campaign enlisted women’s advocacy groups, many of which received pharmaceutical funding, and pressured the FDA through petitions, congressional lobbying, and media coverage.

In 2015, the FDA approved flibanserin under the brand name Addyi, sometimes called “the female Viagra.” The approval came with a black box warning about its interaction with alcohol.

The Reality

In clinical trials, flibanserin produced, on average, about one additional “satisfying sexual event” per month compared to placebo. Women taking flibanserin reported approximately 4.4 satisfying sexual events per month, compared to 3.7 on placebo. For this marginal benefit, women were required to take a pill every single day, avoid all alcohol, and risk significant side effects.

Addyi’s commercial performance was dismal. Within a year, Sprout was sold to Valeant Pharmaceuticals for $1 billion, but actual prescriptions were a fraction of projections. Physicians and patients alike recognized that the product didn’t deliver on the hype.

What It Reveals About Diseases Invented by Drug Companies

The FSD case reveals the full machinery at work:

• A normal spectrum of human sexual experience was pathologized using an inflated statistic.
• Industry-funded researchers laid the scientific groundwork.
• A failed drug was repurposed and aggressively marketed.
• A “disease awareness” campaign was wrapped in the language of gender equality to pressure regulators.
• The actual clinical benefit was trivially small.

Dr. Leonore Tiefer, a clinical psychologist and sex therapist who led the “New View Campaign” opposing the medicalization of women’s sexuality, called the FSD movement “a textbook case of disease mongering.” She argued that framing the full diversity of women’s sexual experiences as a medical disorder does women a disservice by medicalizing problems that are often relational, cultural, or psychological.

Case #3: Prediabetes and How Drug Companies Sell Medications to the Almost-Sick

Of all the diseases invented by drug companies, or at least heavily influenced by them, the story of “prediabetes” may affect the largest number of people. It is a case study in how lowering a diagnostic threshold can, overnight, turn tens of millions of healthy people into patients.

The Numbers Are Staggering

According to the Centers for Disease Control and Prevention, approximately 96 million American adults have prediabetes. That’s more than one in three. Globally, similar proportions are claimed, with the International Diabetes Federation estimating that hundreds of millions of people worldwide are “prediabetic.”

Stop and think about that for a moment. When a diagnostic label applies to a third of the adult population, is it still describing a disease? Or is it describing a range of normal human variation?

What Is Prediabetes?

Prediabetes is defined as having blood sugar levels higher than normal but not yet high enough to qualify as Type 2 diabetes. Specifically:

• Fasting blood glucose of 100–125 mg/dL (normal is below 100; diabetes is 126 or above)
• HbA1c (a measure of average blood sugar over 2–3 months) of 5.7%–6.4% (normal is below 5.7%; diabetes is 6.5% or above)

The concept seems straightforward. People with prediabetes are “on their way” to diabetes and should be treated early. But the story is more complicated than it appears.

The Threshold Problem

The diagnostic thresholds for prediabetes have been lowered repeatedly over the decades. In 2003, the American Diabetes Association (ADA) lowered the fasting glucose threshold for prediabetes from 110 mg/dL to 100 mg/dL. This single change added approximately 26 million more Americans to the prediabetes category overnight.

The expert panel that recommended this change included members with financial ties to pharmaceutical companies that manufacture diabetes drugs, including metformin and the newer (and much more expensive) classes of diabetes medications.

Does Prediabetes Predict Diabetes?

Here’s where it gets really interesting. The assumption behind the prediabetes label is that these individuals are destined, or at least very likely, to progress to full diabetes. But the evidence doesn’t support this.

A comprehensive review published in the British Medical Journal found that the majority of people classified as prediabetic never develop Type 2 diabetes. Depending on the study and the follow-up period, only about 5% to 10% of prediabetic individuals progress to diabetes each year, and many actually return to normal glucose levels without any intervention.

In other words, for most people labeled “prediabetic,” the condition resolves on its own.

Who Benefits?

Despite this, the prediabetes label creates enormous commercial opportunities:

• Pharmaceutical sales. Metformin is increasingly prescribed to prediabetic patients, and newer, more expensive drugs like GLP-1 receptor agonists are being studied and marketed for this population.
• Blood glucose monitoring. The continuous glucose monitor (CGM) market has exploded, with companies now marketing these devices to non-diabetic individuals who want to track their “metabolic health.”
• Supplements and wellness products. The prediabetes label has spawned a cottage industry of blood sugar supplements, special diets, and coaching programs.
• Medical visits and testing. Prediabetic patients are encouraged to return for regular monitoring, generating recurring revenue for healthcare systems.

The Healthy Lifestyle Smokescreen

Proponents of the prediabetes diagnosis argue that even if most people don’t progress, the label motivates healthy lifestyle changes. There is some truth to this. The landmark Diabetes Prevention Program trial showed that lifestyle interventions (diet and exercise) reduced progression to diabetes by 58%.

But critics point out that you don’t need a disease label to tell people that eating well and exercising are good ideas. And the label comes with real costs: anxiety, insurance implications, the psychological burden of being told you’re “pre-diseased,” and the increasing pressure to take medication for a “condition” that would likely resolve with modest lifestyle changes.

Dr. John Yudkin, a professor of medicine at University College London, co-authored a widely cited BMJ paper arguing that the prediabetes label “carries more risk than benefit” and that “pathologizing normal aging and a normal range of glucose values serves commercial rather than public health interests.”

Case #4: Low Testosterone (“Low T”) and Drug Companies That Sell Medications for Aging

Few cases illustrate diseases invented by drug companies as vividly as the “Low T” (low testosterone) phenomenon of the early 2000s and 2010s. It is a case study in how a pharmaceutical industry can take a normal biological process (aging), rebrand it as a disease, and sell a treatment to millions.

The Natural Decline

Testosterone levels in men decline naturally with age. This is a well-established biological fact. Beginning around age 30, testosterone drops by roughly 1% to 2% per year. By the time a man is 60 or 70, his testosterone levels may be significantly lower than they were at 25.

This is not a disease. It is aging. Just as hair grays, skin wrinkles, and metabolism slows, testosterone declines. It has been happening to every man who has ever lived long enough to experience it.

The Invention of “Low T”

In the early 2000s, several pharmaceutical companies, including Abbott Laboratories (maker of AndroGel), Eli Lilly (maker of Axiron), and AbbVie (which later acquired AndroGel), launched aggressive campaigns to rebrand this natural decline as a medical condition called “Low T.”

The campaigns were sophisticated and multi-pronged:

• Direct-to-consumer advertising. Television commercials showed middle-aged men experiencing fatigue, low mood, decreased libido, and weight gain, and asked: “Could it be Low T?” The ads directed viewers to “Is it Low T?” websites where they could take self-assessment quizzes.
• Broadened diagnostic criteria. The campaigns encouraged the use of total testosterone thresholds that classified a large percentage of older men as “deficient,” even though their levels were entirely normal for their age.
• Physician education. AbbVie funded continuing medical education programs for physicians, sponsored medical conferences, and deployed sales representatives to promote testosterone testing and prescribing.
• Celebrity endorsements and media placement. Low T became a media staple, with stories appearing in men’s health magazines, TV segments, and newspaper articles.

The Prescription Explosion

The campaign worked spectacularly. Between 2001 and 2013, testosterone prescriptions in the United States increased by more than 500%. AndroGel alone generated over $1 billion in annual revenue at its peak.

Millions of men who were experiencing the normal effects of aging, tiredness, reduced sex drive, a few extra pounds, were told they had a medical condition and given a hormone replacement therapy.

The Safety Backlash

Then the safety data began to emerge. Multiple studies raised concerns about an increased risk of cardiovascular events, including heart attacks and strokes, in men taking testosterone therapy. A 2013 study published in JAMA found a 30% increased risk of adverse cardiovascular outcomes in men who received testosterone prescriptions.

The FDA stepped in, issuing warnings and eventually requiring updated labeling on testosterone products. The agency also explicitly stated that testosterone therapy should not be used for age-related decline alone and should be reserved for men with a genuine medical condition (hypogonadism) confirmed by both low blood levels and specific clinical symptoms caused by a disease or injury.

In other words, the FDA was essentially saying: Low T, as marketed, was not a real disease.

The Lawsuits

Thousands of men filed lawsuits against AbbVie and other manufacturers, alleging that the companies had overstated the benefits and downplayed the risks of testosterone therapy. AbbVie settled a significant number of these cases.

The Takeaway

The Low T story is a near-perfect illustration of the disease mongering playbook:

• A normal biological process was reframed as a medical condition.
• Diagnostic criteria were set to capture a maximally large population.
• Aggressive direct-to-consumer advertising created patient demand.
• Physicians were educated (influenced) to prescribe.
• Safety concerns were downplayed until they became undeniable.
• The company profited enormously before the backlash arrived.

Today, testosterone prescriptions have declined significantly from their peak, but the Low T brand remains embedded in public consciousness, and many men still take testosterone for age-related decline despite the FDA’s warnings.

Case #5: Restless Legs Syndrome and the Drug Companies That Sell Medications for Uncomfortable Feelings

Restless Legs Syndrome (RLS) is a real condition. Let’s say that clearly at the outset. Some people experience genuinely debilitating, uncontrollable urges to move their legs, particularly at night, that severely impair their sleep and quality of life. For those individuals, treatment is appropriate and valuable.

But the story of how RLS went from an obscure, rarely diagnosed condition to a mainstream “epidemic” affecting millions is one of the most instructive examples of diseases invented by drug companies to sell medications.

The Obscure Condition

RLS was first described in the medical literature in 1945 by Swedish neurologist Karl-Axel Ekbom. For decades, it remained a curiosity, diagnosed in a small number of patients with severe symptoms. Most physicians had barely heard of it.

Then GlaxoSmithKline developed ropinirole (Requip), a dopamine agonist originally used for Parkinson’s disease. GSK needed a broader market.

The Awareness Campaign

In the early 2000s, GSK launched a massive disease awareness campaign for RLS. The campaign followed the now-familiar playbook:

• Prevalence inflation. GSK-funded studies claimed that RLS affected “up to 10% of the U.S. population,” or roughly 30 million people. The criteria used were extremely broad, including people who experienced occasional, mild leg discomfort.
• Patient “awareness” materials. GSK created educational materials, websites, and TV segments designed to help people “recognize” RLS symptoms in themselves.
• Physician outreach. Sales representatives visited doctors’ offices armed with diagnostic checklists and prescribing information.
• Media coverage. RLS suddenly appeared in health segments on morning shows, in newspaper health columns, and in magazine articles. Much of this coverage was seeded by GSK’s public relations efforts.

The Diagnostic Creep

The criteria for diagnosing RLS became remarkably vague. The four core diagnostic features are:

1. An urge to move the legs, usually accompanied by uncomfortable sensations
2. Symptoms begin or worsen during rest or inactivity
3. Symptoms are partially or totally relieved by movement
4. Symptoms are worse in the evening or at night

By these criteria, a wide range of common experiences qualify: restlessness after sitting too long, leg discomfort during a boring meeting, the need to stretch after lying in bed. The line between “occasional uncomfortable restlessness” and “Restless Legs Syndrome” became exceedingly thin.

The Numbers

In 2005, the FDA approved Requip for RLS. Sales surged. By 2008, Requip was generating hundreds of millions of dollars in revenue, with RLS constituting a significant portion of prescriptions.

The Side Effects

Dopamine agonists like ropinirole carry notable side effects, including nausea, dizziness, and, most strikingly, impulse control disorders. Patients taking these drugs have reported compulsive gambling, hypersexuality, binge eating, and compulsive shopping. For a condition that, in many patients, amounts to mild nighttime restlessness, these are serious risks.

The Expert Pushback

Dr. Steven Woloshin and Dr. Lisa Schwartz, both physician-researchers at the Dartmouth Institute for Health Policy and Clinical Practice, published an influential analysis of the RLS awareness campaign. They found that GSK’s campaign systematically:

• Exaggerated the prevalence and severity of RLS
• Minimized the side effects of ropinirole
• Failed to mention non-drug alternatives (such as exercise, reduced caffeine intake, and improved sleep hygiene)
• Framed a common, often mild experience as a serious medical disorder

Their research, published in PLOS Medicine, remains one of the most cited analyses of pharmaceutical disease mongering.

The Bigger Picture: Why Diseases Invented by Drug Companies Matter for Public Health

At this point, you might be asking a reasonable question: even if drug companies exaggerate or invent diseases, does it really matter? If the medications help some people, what’s the harm?

The harm is significant, and it operates on multiple levels.

Harm to Individuals

Every medication carries side effects. When a drug is prescribed to someone who genuinely needs it, the benefit-to-risk calculation usually favors treatment. But when millions of essentially healthy people are medicated for conditions they don’t truly have, the math changes dramatically.

• Millions of men took testosterone and faced elevated cardiovascular risk for a “disease” that was actually normal aging.
• Millions of women were told they were sexually dysfunctional based on a flawed statistic.
• Tens of millions of people were labeled “prediabetic” and pushed toward medication for a condition most would never develop.
• People taking dopamine agonists for mild restless legs developed gambling addictions.
• Individuals prescribed Paxil for ordinary shyness experienced severe withdrawal symptoms.

These are not abstract concerns. These are real consequences suffered by real people.

Harm to the Healthcare System

When diagnostic categories are expanded to capture tens of millions of new “patients,” healthcare costs explode. Resources that could be directed toward people with genuine, severe illness are instead spent on medicating the worried well.

The U.S. healthcare system already spends more per capita than any other developed nation while producing mediocre outcomes. The medicalization of normal life is one contributor to this dysfunction.

Harm to Trust

Perhaps most insidiously, when people learn that pharmaceutical companies have manufactured diseases to sell drugs, it erodes trust in the entire medical system. This erosion has real consequences. People become skeptical of legitimate diagnoses. They distrust their doctors. They refuse medications they genuinely need. They turn to unproven alternative treatments.

The pharmaceutical industry’s disease mongering doesn’t just harm the people it directly targets. It harms everyone, by poisoning the well of public trust in medicine.

Harm to Science

When industry funding influences which conditions are studied, how diagnostic criteria are defined, and which treatment guidelines are adopted, the scientific process itself is compromised. Research priorities are driven by market potential rather than public health need. Conditions that affect the poor, or for which no patentable treatment exists, are neglected.

How to Recognize When Drug Companies Are Selling Medications Through Disease Invention

Armed with the knowledge of how the playbook works, you can learn to spot disease mongering in real time. Here are the red flags to watch for.

The Warning Signs

• A “new” condition appears suddenly in the media. If you’ve never heard of a disease, and suddenly it’s everywhere, ask who’s funding the awareness campaign.
• Prevalence estimates are shockingly high. When a condition supposedly affects 10%, 20%, or 30% of the population, be skeptical. The broader the claimed prevalence, the bigger the market.
• The awareness campaign arrives just before or after a drug approval. This is not a coincidence.
• Vague, subjective diagnostic criteria. If the diagnostic criteria sound like they could apply to almost anyone on a bad day, the boundaries have probably been drawn too broadly.
• Direct-to-consumer advertising asks, “Could you have…?” This is designed to create self-diagnosis and drive patients to request specific medications from their doctors.
• Celebrity spokespeople and patient advocacy groups. Check the funding. Many “grassroots” patient organizations receive the majority of their funding from pharmaceutical companies.
• The recommended treatment is always medication. If lifestyle changes, watchful waiting, and non-drug therapies are barely mentioned, someone is selling something.
• The “experts” have industry ties. Check conflict-of-interest disclosures. If the researchers, guideline authors, and media commentators all receive money from the same company, approach their claims with healthy skepticism.

A Practical Checklist

When you encounter a new diagnosis, health claim, or disease awareness campaign, ask yourself:

1. Who is funding this?
2. How is the condition defined, and have the criteria recently been expanded?
3. What percentage of the population supposedly has it?
4. What are the alternatives to medication?
5. What are the side effects of the recommended treatment?
6. Do the researchers and guideline authors have financial ties to the industry?

These questions won’t make you a medical expert, but they will make you a much more informed consumer of health information.

Step-by-Step Guide: How to Protect Yourself from Disease Mongering

Knowing the playbook is one thing. Taking concrete action is another. Here is a practical, step-by-step guide to protecting yourself and your family from diseases invented by drug companies.

Step 1: Become a Skeptical Consumer of Health News

Not all health news is created equal. Before accepting a new diagnosis or disease claim, look for the following:

• Is the study published in a reputable, peer-reviewed journal?
• Who funded the research?
• Is the news story based on a press release from a pharmaceutical company?
• Are independent experts quoted, or only researchers with industry ties?

Step 2: Research Your Diagnosis

If a doctor gives you a new diagnosis, especially one you haven’t heard of before, take time to research it before starting treatment.

• Look up the condition on independent sources like the National Institutes of Health (NIH) MedlinePlus or Cochrane Reviews.
• Ask your doctor: “What is the evidence that this condition requires medication?” and “What are the non-drug alternatives?”
• Seek a second opinion if anything feels rushed or pressured.

Step 3: Ask About Diagnostic Thresholds

If your diagnosis is based on a number (blood sugar, cholesterol, testosterone, bone density), ask:

• When were these thresholds last changed?
• Who set them, and did they have industry ties?
• What is my actual risk of a bad outcome, given my specific numbers and overall health?
• Would lifestyle changes alone be a reasonable first approach?

Step 4: Investigate the Drug

Before starting any new medication, ask:

• What are the benefits, and how large are they? (A drug that produces one additional “satisfying sexual event per month” is very different from a drug that prevents heart attacks.)
• What are the side effects, and how common are they?
• How long will I need to take it?
• What happens if I stop?
• Are there non-drug alternatives with similar effectiveness?

Step 5: Check for Industry Ties

This is easier than you might think. Several online databases allow you to check whether your doctor receives payments from pharmaceutical companies:

• Open Payments (cms.gov/openpayments) is a U.S. government database of industry payments to physicians.
• Dollars for Docs (ProPublica) provides a searchable interface for the same data.

Having industry ties doesn’t automatically make a doctor untrustworthy, but it’s information worth having.

Step 6: Prioritize Lifestyle Interventions

For many of the conditions discussed in this article, lifestyle changes (diet, exercise, stress management, sleep) are at least as effective as medication, often more so, and carry none of the side effects.

• The Diabetes Prevention Program showed lifestyle changes were 58% effective at preventing progression to diabetes, compared to 31% for metformin.
• Exercise has been shown to be as effective as antidepressants for mild to moderate depression.
• Cognitive behavioral therapy is as effective as medication for many anxiety disorders, with no side effects and longer-lasting results.

Step 7: Advocate for Transparency

Support organizations and journalists that investigate pharmaceutical industry practices. Subscribe to independent health media. Share articles like this one with friends and family. The more people understand the disease mongering playbook, the less effective it becomes.

Comparison Table: Diseases Invented by Drug Companies, the Evidence at a Glance

The following table summarizes the five cases we’ve examined, providing a quick-reference overview of how drug companies sell medications through disease creation.

Beyond These Five: Other Conditions Where Drug Companies Sell Medications by Expanding Disease Definitions

The five cases we’ve examined in depth are among the best-documented, but they are far from the only examples of diseases invented or expanded by drug companies to sell medications. Here’s a brief survey of other conditions where similar dynamics have been observed.

Overactive Bladder (OAB)

Before the late 1990s, urinary urgency was considered a symptom, not a disease. Then pharmaceutical companies developed anticholinergic drugs to treat it and launched awareness campaigns encouraging people to “talk to your doctor about OAB.” Overnight, a common experience, especially among older adults, became a diagnosable medical condition.

The drugs prescribed for OAB have since been linked to increased risk of cognitive decline and dementia in older adults, the very population most likely to be prescribed them.

Osteopenia

Osteopenia is defined as bone density that is lower than normal but not low enough to qualify as osteoporosis. It was essentially created as a diagnostic category in the 1990s, when the World Health Organization established bone density thresholds. The threshold for osteopenia was set so broadly that the majority of postmenopausal women qualify.

Drug companies, particularly Merck (maker of the bisphosphonate drug Fosamax), aggressively promoted bone density screening and the treatment of osteopenia. Yet many experts have argued that osteopenia represents normal age-related bone changes, not a disease, and that the fracture risk for most women with osteopenia is very low.

Attention Deficit Hyperactivity Disorder (ADHD) in Adults

ADHD is a legitimate neurodevelopmental condition that significantly impairs the functioning of many children and adults. However, the expansion of ADHD diagnosis into adult populations has been accompanied by aggressive marketing by manufacturers of stimulant medications.

The number of adults diagnosed with ADHD has surged in recent years, fueled in part by social media, direct-to-consumer advertising, and online “assessment” tools. Some researchers have expressed concern that the diagnostic criteria have been applied so broadly that normal variations in attention, focus, and executive function are being pathologized.

Chronic Lyme Disease

While acute Lyme disease is a well-established, treatable bacterial infection, “Chronic Lyme Disease” is a controversial diagnosis promoted by a segment of the medical community. It has no standardized diagnostic criteria, no validated lab test, and no proven treatment. Yet it has become a multimillion-dollar industry, with patients often prescribed prolonged courses of antibiotics, unproven supplements, and expensive alternative therapies.

What the Medical Community Says About Diseases Invented by Drug Companies

It would be misleading to suggest that the medical community is monolithic on this issue. There is genuine debate, and reasonable physicians disagree about where to draw the line between legitimate diagnosis and disease mongering.

The Critics

A growing number of physicians, researchers, and public health experts have raised the alarm about pharmaceutical disease creation:

• Dr. Ray Moynihan (Bond University, Australia) has published extensively on disease mongering and is the author of Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All Into Patients.
• Dr. Marcia Angell (former editor of the New England Journal of Medicine) has described the pharmaceutical industry as “primarily a marketing machine” and has written about its influence on clinical practice.
• Dr. Allen Frances (who chaired the DSM-IV task force) has warned that diagnostic inflation is turning normal people into patients and has specifically criticized the expansion of conditions like ADHD, bipolar disorder, and autism spectrum disorder.
• Dr. Peter Gøtzsche (co-founder of the Cochrane Collaboration) has described the pharmaceutical industry’s practices as “organized crime” and has documented systematic manipulation of clinical trials.

The Defenders

Others argue that expanding diagnostic categories and increasing awareness of underdiagnosed conditions is a net positive. They point out that:

• Many people with legitimate conditions went undiagnosed and untreated before awareness campaigns.
• Early intervention can prevent progression of disease.
• Not all pharmaceutical marketing is deceptive, and many drugs provide genuine benefit.
• Critics sometimes overcorrect, leading patients to refuse beneficial treatments.

The Middle Ground

The most balanced view, and the one this article tries to represent, acknowledges both realities. Pharmaceutical companies have produced genuinely valuable treatments. Some awareness campaigns have helped people get diagnoses and treatments that improved their lives. At the same time, the profit motive creates powerful incentives to expand disease definitions beyond what the science supports, and the evidence shows that this happens regularly.

The solution is not to reject all pharmaceutical medicine. It’s to demand transparency, independent research, and evidence-based diagnostic criteria free from industry influence.

How Regulation Has (and Hasn’t) Addressed Diseases Invented by Drug Companies

Given the scale of the problem, you might expect robust regulatory safeguards. The reality is more complicated.

What the FDA Does

The U.S. Food and Drug Administration regulates drug safety and efficacy. It requires pharmaceutical companies to demonstrate that their products are safe and effective through clinical trials before approval. However, the FDA does not regulate:

• Disease definitions or diagnostic criteria (these are set by professional organizations, often with industry input)
• “Disease awareness” campaigns (these are considered educational, not promotional, and are largely unregulated)
• Off-label prescribing (once a drug is approved for one indication, doctors can prescribe it for anything)

The Direct-to-Consumer Advertising Problem

The United States is one of only two countries in the world (the other is New Zealand) that permits direct-to-consumer (DTC) advertising of prescription drugs. This means pharmaceutical companies can market directly to patients through TV, print, radio, and digital advertising.

DTC advertising is a major driver of disease mongering, as it enables companies to simultaneously “raise awareness” of a condition and promote the drug that treats it. Multiple studies have shown that DTC advertising increases prescribing of the advertised drug, often inappropriately.

The American Medical Association has called for a ban on DTC advertising. As of this writing, no such ban has been enacted.

Sunshine Laws

The Physician Payments Sunshine Act (2010) requires pharmaceutical companies to disclose payments to physicians, which are then published in the Centers for Medicare & Medicaid Services Open Payments database. This has increased transparency, but it hasn’t stopped the practice of industry influence on physician behavior.

What’s Needed

Experts have proposed several reforms to address pharmaceutical disease mongering:

• Ban or restrict direct-to-consumer advertising of prescription medications.
• Require independence on clinical guideline panels, with no members having financial ties to companies that would benefit from the guidelines.
• Mandate registration and disclosure of all disease awareness campaigns, including their funding sources.
• Increase public funding of clinical research to reduce reliance on industry-funded studies.
• Strengthen the FDA’s mandate to evaluate not just drug safety and efficacy but also the legitimacy of the conditions they purport to treat.

The Role of Media in Amplifying Diseases Invented by Drug Companies

The media plays a critical, and often underappreciated, role in pharmaceutical disease creation. Without media coverage, awareness campaigns would fizzle. Without alarming headlines, patients wouldn’t rush to their doctors.

The Media Playbook

Pharmaceutical PR firms understand media dynamics intimately. They know that journalists need stories, and they supply them:

• Press releases are crafted to read like news stories, with alarming statistics, compelling patient narratives, and expert quotes.
• Embargoed studies are provided to journalists in advance, with helpful “explainer” materials and pre-arranged interviews with the study’s (industry-funded) authors.
• Patient spokespeople are recruited and coached to share their stories with reporters.
• Video news releases (VNRs), essentially pre-made TV segments produced by PR firms, are distributed to local TV stations, which sometimes air them as their own reporting.

Health Journalism’s Challenges

Health journalists are often working under tight deadlines with limited resources. Few have the time or expertise to read clinical trial data, assess diagnostic criteria, or investigate funding sources. The result is that many health stories are, in effect, repackaged pharmaceutical press releases.

Organizations like HealthNewsReview.org (now defunct, but its archives remain valuable) spent years evaluating health news stories and found that the majority failed to adequately address:

• The magnitude of benefits (using relative rather than absolute numbers)
• The harms and side effects of treatments
• The quality of the evidence
• Conflicts of interest
• Non-drug alternatives

What You Can Do

Be a critical consumer of health news. When you see a story about a “new” condition or treatment:

• Look for the funding source.
• Check whether the story mentions side effects and alternatives.
• See if independent experts are quoted, not just those affiliated with the company.
• Search for the original study and see who funded it.

The Psychological Impact of Being Told You Have a Disease Invented by Drug Companies

One dimension of disease mongering that receives insufficient attention is the psychological impact on individuals who are labeled with manufactured or inflated diagnoses.

The Nocebo Effect

Just as the placebo effect can produce genuine improvements through positive expectations, the nocebo effect can produce genuine harm through negative expectations. When a person is told they are “prediabetic,” “Low T,” or have “Female Sexual Dysfunction,” the label itself can become a self-fulfilling prophecy.

Research has shown that diagnostic labels can:

• Increase anxiety and depression
• Cause people to perceive themselves as sicker than they are
• Lead to reduced physical activity and social engagement (because “I’m sick”)
• Create dependence on medication and the medical system
• Damage self-image and identity

The Identity Shift

When a pharmaceutical company successfully convinces a shy person that they have Social Anxiety Disorder, or a middle-aged man that his fatigue is Low T, it fundamentally changes how that person sees themselves. They shift from “a person with a trait” to “a patient with a disease.” That shift has profound psychological consequences.

Dr. H. Gilbert Welch, author of Overdiagnosed: Making People Sick in the Pursuit of Health, has written eloquently about this phenomenon. He argues that overdiagnosis, the detection and labeling of conditions that would never cause symptoms or harm, is “one of the biggest problems in modern medicine.”

What the Future Holds: Emerging Diseases That Drug Companies May Be Inventing to Sell Medications

If history is any guide, the disease mongering playbook will continue to be deployed. Several emerging trends suggest new frontiers for pharmaceutical disease creation.

“Brain Health” and Cognitive Decline

As the population ages, there is enormous market potential in the area of cognitive decline. Companies are already developing drugs for “mild cognitive impairment” (MCI), a condition that, like prediabetes, exists in a gray zone between normal aging and genuine disease.

The recently approved (and controversial) Alzheimer’s drug aducanumab (Aduhelm) was approved by the FDA over the objections of its own advisory committee, raising concerns about industry influence on the regulatory process.

“Subclinical” Conditions

The prefix “sub-clinical” (meaning “below the threshold for diagnosis”) is increasingly being used to create new patient populations. Subclinical hypothyroidism, subclinical depression, subclinical anxiety. Each of these represents a potential market of millions.

Digital Health and Self-Diagnosis

The rise of health-tracking technology (smartwatches, continuous glucose monitors, sleep trackers, genetic testing) is creating entirely new categories of “worry well” consumers who identify abnormalities in their data and seek medical treatment.

Pharmaceutical and device companies are actively cultivating this market, encouraging healthy people to monitor their bodies obsessively and seek treatment for “findings” that may have no clinical significance.

The Microbiome and Gut Health

The human microbiome is a genuine area of scientific interest, but it is also ripe for commercial exploitation. Companies are already marketing probiotics, microbiome tests, and “gut health” supplements based on preliminary science and exaggerated claims. As the field matures, expect pharmaceutical companies to develop drugs targeting the microbiome, accompanied by awareness campaigns about newly defined “disorders.”

Empowering Yourself: The Final Word on Diseases Invented by Drug Companies

If you’ve read this far, you now know more about pharmaceutical disease creation than the vast majority of the public. That knowledge is power, but only if you use it wisely.

What This Knowledge Does NOT Mean

• It does not mean that all diseases are fake.
• It does not mean that all pharmaceutical drugs are bad.
• It does not mean that you should stop taking your medications.
• It does not mean that your doctor is corrupt.
• It does not mean that science is untrustworthy.

What This Knowledge DOES Mean

• You should ask more questions about new diagnoses.
• You should investigate who funds disease awareness campaigns.
• You should understand the difference between a modest statistical benefit and a life-changing treatment.
• You should demand transparency from your healthcare providers.
• You should consider lifestyle interventions before (or alongside) medication for many conditions.
• You should support independent medical research and journalism.

A Shift in Perspective

The most important thing you can take from this article is a shift in perspective. When you see a health commercial, read a health news story, or receive a new diagnosis, you now have the tools to ask: “Who benefits from me believing this?”

That single question, asked consistently and honestly, is your best defense against diseases invented by drug companies to sell medications you may not need.

Conclusion

The pharmaceutical industry’s role in creating, expanding, and popularizing disease categories to sell medications is not a conspiracy theory. It is a well-documented, extensively studied phenomenon that has been the subject of peer-reviewed research, investigative journalism, government inquiries, and legal action.

From the rebranding of shyness as Social Anxiety Disorder to the invention of “Low T” as a treatable condition, from the inflated statistics behind Female Sexual Dysfunction to the threshold manipulation that created 96 million American “prediabetics,” the evidence shows that diseases invented by drug companies have been a consistent feature of modern medicine for decades.

This does not make the pharmaceutical industry uniquely evil. Every industry markets its products. But the stakes in healthcare are uniquely high. When a car company exaggerates the performance of its vehicle, you get a disappointing test drive. When a pharmaceutical company exaggerates the prevalence of a disease, millions of people take drugs they don’t need and suffer side effects that wouldn’t have occurred if they’d simply been told, “You’re fine.”

The antidote to disease mongering is not paranoia. It’s not rejecting modern medicine. It’s not throwing your pills in the trash. The antidote is informed skepticism, the willingness to ask questions, seek independent information, and make healthcare decisions based on evidence rather than marketing.

You deserve to make health decisions based on your actual needs, not on a pharmaceutical company’s revenue targets. And now you have the knowledge to do exactly that.

Did this article change how you think about medical diagnoses? Share it with someone who needs to see this. Drop a comment below with your own experiences, and let’s keep this conversation going.

This article is regularly updated to reflect the latest research on pharmaceutical marketing practices and disease mongering. Last reviewed: 2024.